Wyeth selects novel drug targets in osteoporosis collaboration with Galapagos Genomics NV
10 Nov 2004 -
Galapagos Genomics announced that it has reached a research milestone in its osteoporosis discovery program with Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth. Within the program, which was initiated November 2003, Galapagos has used its osteoporosis disease expertise in combination with its SilenceSelect(TM) adenoviral siRNA platform to discover and validate novel drug targets that may affect bone remodeling. Wyeth has now selected a set of these targets for internal development, triggering a financial milestone for Galapagos. As these targets are progressed by Wyeth, Galapagos has rights to additional milestone payments that could amount up to $40 million.
"We are excited that we have successfully delivered on our commitments in our osteoporosis program with Wyeth. The selection of these targets is a critical decision as it forms the basis for the development of novel medicines," said Onno van de Stolpe, CEO of Galapagos. "The milestone by Wyeth underlines the power of the SilenceSelect platform as a powerful tool to discover novel drug targets and confirms the strength of our discovery biology research team in osteoporosis".
Top
Contact
Print version
PDF version
Send article
RSS feed
